Get all your news in one place.
100’s of premium titles.
One app.
Start reading
Benzinga
Benzinga
Technology
Vandana Singh

Halozyme's Q4 Earnings Beat Consensus Despite Lower Product Sales Hit Topline Growth

Halozyme Therapeutics Inc (NASDAQ:HALOreported Q4 revenue of $102 million compared to $121.7 million a year ago, beating the consensus of $100.32 million. 

  • The decrease was primarily driven by a decline in revenue under collaboration agreement and product sales, partially offset by an increase in royalty revenue attributable to subcutaneous Darzalex (daratumumab). 
  • Revenue for Q4 included $62.6 million in royalties.
  • Adjusted EPS of $0.42 beat the consensus of $0.41.
  • The Company reported an operating income of $56.5 million, down from $77.6 million a year ago.
  •  "In 2022, we look forward to building on 2021 momentum and anticipate 50% growth in our high-margin, recurring royalty revenues driven by further adoption of wave 2 products. We project further expansion and maturing of our pipeline, with 4 new targets entering Phase 1 development and at least 5 products advancing to Phase 2 or Phase 3 development," noted Helen Torley, president & CEO.
  • FY22 Guidance: Halozyme expects revenues of $530 million - $560 million (consensus of $554.20 million) and expects revenue from royalties to increase approximately 50% Y/Y to roughly $300 million.
  • It expects an adjusted EPS of $2.05 - $2.20, compared to the consensus estimate of $2.18.
  • Halozyme forecasts operating income of $350 million - $380 million, up 27% - 38% Y/Y, representing a margin of over 65%.
  • Price Action: HALO shares closed at $32.79 on Tuesday.
Sign up to read this article
Read news from 100’s of titles, curated specifically for you.
Already a member? Sign in here
Related Stories
Top stories on inkl right now
Our Picks
Fourteen days free
Download the app
One app. One membership.
100+ trusted global sources.